Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
about
Positive and negative functions of B lymphocytes in tumorsCD40 in coronary artery disease: a matter of macrophages?A Short History of the B-Cell-Associated Surface Molecule CD40The Immunogenetics of Autoimmune CholestasisA phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Granulocyte-Colony Stimulating Factor related pathways tested on an endometrial ex-vivo modelCD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT miceLocal Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy.Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation.Regulation of atherosclerotic plaque inflammation.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Emerging immunological drugs for chronic lymphocytic leukemia.Prognostic Biomarkers for Hodgkin Lymphoma.Vaccines targeting helper T cells for cancer immunotherapy.AFM study shows prominent physical changes in elasticity and pericellular layer in human acute leukemic cells due to inadequate cell-cell communication.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and AdjuvantsEmerging antibodies for the treatment of multiple myeloma.Checkpoint inhibition for colorectal cancer: progress and possibilities.Oncolytic virotherapy for urological cancers.Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V-Induced Squamous Tumors.Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria, independent of blood pressure.A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitmentExpression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).The RNA-Binding Protein, Polypyrimidine Tract-Binding Protein 1 (PTBP1) Is a Key Regulator of CD4 T Cell Activation.A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members.The CD40/CD40L axis in glioma progression and therapy.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
P2860
Q26743398-07E5DF18-4B4E-4080-A5CC-79BBB7745082Q26752784-410EA78E-653C-4699-8E56-CDF835FF9D6DQ27007137-632AEC62-7AE7-48D6-B08B-B212D9046869Q28085346-D02CDDBA-E73A-428C-8598-7568C73F6CFAQ33415880-B319B671-ED0F-4FF4-AAF7-0F81021B87F3Q34281982-576684DB-E42A-4F68-9081-56AA056E6452Q36022324-D21984DF-EC47-4CCF-B4D4-4197698804CBQ36777155-D6DDA123-05F5-4E59-9DA0-A6724D1A1612Q36980415-F7C52A51-1BE8-454B-AD28-3E3489C87EEAQ37412470-EE90539A-73F9-4D31-9865-2201DD0C9BCDQ38396097-804C9A05-3DEA-4A19-8949-9B77BF0C3A2DQ38406177-EDE0D72C-1AA7-45CE-8237-06BC3836EE2BQ38445336-F625F6CD-8893-4669-998C-5B92F67E466CQ38543771-AE28F415-11A4-4C70-A937-F6BF8457DD32Q38588503-328E8682-B7BA-4171-A5DF-AFFD11DB2D17Q38649958-172071A0-BDC8-4A8A-A463-48F726A396B8Q38731813-D154CB96-139D-40CC-A37A-F30B63B0FDABQ38737970-A208ACF9-81C7-44CC-87DC-7478F0B4FFDFQ38759934-BDD16CD4-EA54-46D9-A805-23E2A825A153Q38838239-AEDC262C-6941-4660-9159-6453FCE739EAQ38838641-42E20B69-D50A-4323-B4F6-596F855AA687Q38842126-78DBE67E-AA0D-473B-9888-895720458A02Q38991275-A1E3B6A7-4635-46EB-A78E-97338A09A43DQ39191316-05980A5D-4ED0-4B2A-80E4-5C5C9B962E1CQ39332611-9782562D-E553-48BC-97A3-24D5C3587BB2Q40095340-25EB3024-1436-4917-B3C9-8880381C7FA7Q41269256-308DCBED-715E-4B76-819F-DF9E4725873FQ41788230-FB2FB5D1-104D-41F8-8506-9F4FE10AF1A4Q41954955-EDAC985E-5C52-4FCB-8154-AD0DF84E634DQ42378925-440E4CEA-4E9B-4B4D-8142-F496FC34B07AQ43170417-EB3D5CCA-F55B-4834-BF2F-772BCF65D349Q48958626-510E846B-B875-4AE7-BB85-7FCB21D59548
P2860
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@ast
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@en
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@nl
type
label
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@ast
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@en
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@nl
prefLabel
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@ast
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@en
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@nl
P2093
P2860
P1476
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
@en
P2093
Barbara Nicola Olsen
Jesper Freddie Sørensen
Sufia Butt Hassan
P2860
P304
P356
10.3109/08923973.2014.890626
P577
2014-02-21T00:00:00Z